Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors.
Katrien BlanchartThibaut HeudelPierre ArdouinAdrien LemaitreClément BrietMathieu BignonRémi SabatierDamien LegalloisVincent RouleFarzin BeyguiPublished in: Clinical cardiology (2021)
Our study suggests that GPI may be used safely in combination with recent P2Y12 inhibitors in STEMI patients in association with modern primary percutaneous coronary intervention strategies (radial access and anticoagulation with enoxaparin) with similar bleeding and mortality rates at hospital discharge and 3-month follow-up.
Keyphrases
- percutaneous coronary intervention
- st elevation myocardial infarction
- end stage renal disease
- st segment elevation myocardial infarction
- acute myocardial infarction
- newly diagnosed
- atrial fibrillation
- acute coronary syndrome
- coronary artery disease
- ejection fraction
- chronic kidney disease
- antiplatelet therapy
- peritoneal dialysis
- prognostic factors
- heart failure
- patient reported outcomes
- risk factors